| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $183,167 | 9 | 100 |
| Capps Kathleen S. | See Remarks | 0 | $0 | 2 | $7,486 | $-7,486 |
| Rottinghaus Scott T. | Chief Medical Officer | 0 | $0 | 1 | $11,356 | $-11,356 |
| Trout Harry R. III | See Remarks | 0 | $0 | 2 | $13,017 | $-13,017 |
| Luu Brendan | Chief Business Officer | 0 | $0 | 1 | $19,837 | $-19,837 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 0 | $0 | 1 | $29,968 | $-29,968 |
| Or Yat Sun | Chief Scientific Officer | 0 | $0 | 1 | $34,010 | $-34,010 |
| Luly Jay R. | President and CEO | 0 | $0 | 1 | $67,493 | $-67,493 |
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, …
Over the last 12 months, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $183,167 worth of Enanta Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Enanta Pharmaceuticals, Inc. have bought $256,050 and sold $2.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 45,000 shares for transaction amount of $256,050 was made by Luly Jay R. (President and CEO) on 2025‑02‑12.
| 2025-12-05 | Sale | Luly Jay R. | President and CEO | 4,743 0.0217% | $14.23 | $67,493 | -8.49% | |
| 2025-12-05 | Sale | Or Yat Sun | Chief Scientific Officer | 2,390 0.0109% | $14.23 | $34,010 | -8.49% | |
| 2025-12-05 | Sale | Luu Brendan | Chief Business Officer | 1,394 0.0064% | $14.23 | $19,837 | -8.49% | |
| 2025-12-05 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 2,106 0.0096% | $14.23 | $29,968 | -8.49% | |
| 2025-12-05 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 798 0.0036% | $14.23 | $11,356 | -8.49% | |
| 2025-12-05 | Sale | Trout Harry R. III | See Remarks | 542 0.0025% | $14.23 | $7,713 | -8.49% | |
| 2025-12-05 | Sale | Capps Kathleen S. | See Remarks | 323 0.0015% | $14.23 | $4,596 | -8.49% | |
| 2025-12-02 | Sale | Trout Harry R. III | See Remarks | 380 0.0018% | $13.96 | $5,305 | -3.94% | |
| 2025-12-02 | Sale | Capps Kathleen S. | See Remarks | 207 0.001% | $13.96 | $2,890 | -3.94% | |
| 2025-02-12 | Luly Jay R. | President and CEO | 45,000 0.2147% | $5.69 | $256,050 | +34.81% | ||
| 2024-12-06 | Sale | Luly Jay R. | President and CEO | 5,142 0.0244% | $8.06 | $41,445 | -9.63% | |
| 2024-12-06 | Sale | Or Yat Sun | Chief Scientific Officer | 2,591 0.0123% | $8.06 | $20,883 | -9.63% | |
| 2024-12-06 | Sale | MELLETT PAUL J | Chief Fin. & Admin Officer | 2,591 0.0123% | $8.06 | $20,883 | -9.63% | |
| 2024-12-06 | Sale | Luu Brendan | Chief Business Officer | 2,283 0.0108% | $8.06 | $18,401 | -9.63% | |
| 2024-12-06 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 2,283 0.0108% | $8.06 | $18,401 | -9.63% | |
| 2024-12-06 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 866 0.0041% | $8.06 | $6,980 | -9.63% | |
| 2024-07-15 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 5,375 0.0355% | $17.08 | $91,805 | -54.69% | |
| 2024-07-12 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 2,271 0.0132% | $15.04 | $34,156 | -53.13% | |
| 2024-07-11 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 4,299 0.0251% | $15.07 | $64,786 | -49.97% | |
| 2024-06-17 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 7,266 0.0315% | $12.33 | $89,590 | -33.22% |
| Luly Jay R. | President and CEO | 858026 2.946% | $8.9M | 1 | 19 | +34.81% |
| SCHUHSLER HELMUT | 380487 1.3064% | $3.95M | 1 | 3 | +19.31% | |
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | 10 percent owner | 276999 0.9511% | $2.87M | 1 | 7 | +19.31% |
| Gardiner Nathaniel S. | Sr. VP & General Counsel | 68154 0.234% | $706,756.98 | 3 | 2 | +9.2% |
| SAINTS CAPITAL GRANITE, L.P. | 10 percent owner | 16904 0.058% | $175,294.48 | 1 | 8 | +19.31% |
| Vance Terry | director | 5800 0.0199% | $60,146.00 | 2 | 1 | +8.96% |
| Verdine Gregory L. | director | 3324 0.0114% | $34,469.88 | 1 | 0 | +19.31% |
| Buckley Stephen Jr. | director | 2000 0.0069% | $20,740.00 | 3 | 0 | +6.42% |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$104,171,521 | 16 | 20.21% | $275.53M | |
$1,057,969 | 14 | 68.06% | $271.16M |
| Increased Positions | 82 | +64.57% | 10M | +52.58% |
| Decreased Positions | 53 | -41.73% | 2M | -13.02% |
| New Positions | 38 | New | 4M | New |
| Sold Out Positions | 25 | Sold Out | 2M | Sold Out |
| Total Postitions | 156 | +22.83% | 26M | +39.56% |
| Farallon Capital Management Llc | $30,603.00 | 7.32% | 2.12M | 0 | 0% | 2025-09-30 |
| Krensavage Asset Management, Llc | $30,490.00 | 7.29% | 2.11M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $28,075.00 | 6.71% | 1.95M | +1M | +271.73% | 2025-09-30 |
| Vanguard Group Inc | $27,958.00 | 6.69% | 1.94M | -37,843 | -1.91% | 2025-09-30 |
| Blackrock, Inc. | $26,432.00 | 6.32% | 1.83M | -13,925 | -0.75% | 2025-09-30 |
| Millennium Management Llc | $13,671.00 | 3.27% | 948,084 | -510,509 | -35% | 2025-09-30 |
| Acadian Asset Management Llc | $12,503.00 | 2.99% | 867,037 | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $11,536.00 | 2.76% | 800,000 | +800,000 | New | 2025-09-30 |
| Geode Capital Management, Llc | $7,112.00 | 1.7% | 493,194 | +7,397 | +1.52% | 2025-09-30 |
| Renaissance Technologies Llc | $6,916.00 | 1.65% | 479,600 | +10,100 | +2.15% | 2025-09-30 |